CGTIts mainly about the effort.A royalty of at least 10% would have been nice, but even at the current %, if GSK even achieved 30% (to Roche/Tamiflu 70%), we'd be looking at double the royalties.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint
